http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
증례 : 신장 ; 단백질 C와 S 결핍증 환자에서 발생한 자발성 신동맥 박리 1예
임예지 ( Ye Jee Lim ),이래석 ( Rae Seok Lee ),유현아 ( Hyun Ah Yu ),장경윤 ( Kyung Yoon Chang ),서재현 ( Jae Hyun Seo ),이관현 ( Kwan Hyun Lee ),황대연 ( Dae Yeon Hwang ) 대한내과학회 2013 대한내과학회지 Vol.84 No.1
일반적으로 임상에서 신동맥 박리는 대동맥 박리와 연관되어 발생하지만, 외상이나 기저질환이 없이 저절로 발생하는 자발성 신동맥 박리의 경우 알려진 다른 원인이 없거나 반복적인 동정맥 혈전증의 병력이 있을 경우 단백질 C, 단백질 S 등 혈액학적 이상을 확인할 필요가 있겠다. 이에 저자들은 자발성 신동맥 박리와 단백질 C와 S 결핍증이 동반되어 있는 환자를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Spontaneous renal artery dissection without aortic dissection in normotensive patients is rarely reported. Spontaneous renal artery dissection is also an uncommon cause of renal infarction that occurs, though rarely, in patients with hypercoagulable states such as protein C and S deficiency. We report here a case of spontaneous renal artery dissection and renal infarction associated with protein C and S deficiency. (Korean J Med 2013;84:116-119)
Bevacizumab 사용 후 발생한 심한 허혈성 전대장염에서 대증적 요법으로 치료된
이하니 ( Ha Ni Lee ),이명아 ( Myung Ah Lee ),김상우 ( Sang Woo Kim ),임예지 ( Ye Jee Lim ),이화영 ( Hwa Young Lee ),이혜민 ( Hae Min Lee ),원혜성 ( Hye Sung Won ),전상훈 ( Sang Hoon Chun ) 대한소화기학회 2011 대한소화기학회지 Vol.58 No.1
Bevacizumab (Avastin(R)) is a monoclonal antibody against the vascular endothelial growth factor (VEGF) receptor that increases the overall survival rate when added to standard chemotherapy regimens in patients with metastatic colorectal cancer. The known toxicities of bevacizumab are hypertension, proteinuria, wound healing complications, arterial thrombosis, bleeding, and gastrointestinal complications. Especially ischemic colitis can rapidly develop into bowel perforation, so an emergency operation often is needed. Recently, a 65-year-old male patient developed ischemic pancolitis after FOLFOX (85 mg/m2 Oxaliplatin, d1; 200 mg/m2 Leucovorin, d1; 400 mg/m2 5-FU iv bolus, d1-2; and 600 mg/m2 5-FU, d1-2, every two wk) and Bevacizumab combination chemotherapy was administered. However, he recovered after early conservative care without surgery. We report this case with a review of literature. (Korean J Gastroenterol 2011;58:42-46)
김가영 ( Ka Young Kim ),차선아 ( Seon Ah Cha ),김영운 ( Young Woon Kim ),유효경 ( Hyo Kyeong Yu ),임예지 ( Ye Jee Lim ),류시영 ( Si Young You ),김성경 ( Sung Kyoung Kim ),김치홍 ( Chi Hong Kim ),김훈교 ( Hoon Kyo Kim ) 대한결핵 및 호흡기학회 2012 Tuberculosis and Respiratory Diseases Vol.72 No.2
Cough syncope is characterized by the loss of consciousness occurring after vigorous coughings. There are approximately 90 reported cases of cough syncope within the medical literature. Most cases involving middle aged, overweight and chronic bronchitic male smokers. Although many studies have been published in the medical literature, the mechanism and pathophysiology for cough syncope has not been well established. Cough syncope is treated by correcting the underlying cause when identified, or by avoiding conditions that may cause the cough syncope. In addition, cough suppression modalities can also be used. We herein report 3 cases of cough syncope presenting in lung cancer patients.
이수현,정윤영,임예지,고선영,최유아,김영운,이성은,박종원 영남대학교 의과대학 2012 Yeungnam University Journal of Medicine Vol.29 No.1
Plasma cell myelomas generally manifest as bone or soft-tissue tumors with variable mass effects, pain, and infiltrative behavior. Extramedullary involvement occurs most commonly in the spleen, liver, lymph nodes, and kidneys, but intracranial involvement in plasma cell myeloma is a rare extramedullary manifestation. These authors recently encountered a case of intracranial involvement of plasma cell myeloma. A 69-year-old man was hospitalized for headache and mental changes. Brain CT showed subdural hemorrhage caused by plasma cell myeloma. Plasma cell myeloma with intracranial involvement has poor prognosis, and the patient in this case died from acute complications, such as subdural hemorrhage. Based on this case report, it is suggested that more effective treatment regimens of plasma cell myeloma with intracranial involvement be developed. Moreover, a screening method and decision on the appropriate time for intracranial involvement are needed for plasma cell myeloma patients.